SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Biocept Inc – IPO: ‘S-1’ on 9/23/13 – ‘EX-10.17’

On:  Monday, 9/23/13, at 5:23pm ET   ·   Private-to-Public:  Document/Exhibit  –  Release Delayed   ·   Accession #:  1193125-13-374871   ·   File #:  333-191323

Previous ‘S-1’:  None   ·   Next:  ‘S-1/A’ on 10/16/13   ·   Latest:  ‘S-1/A’ on 5/23/23   ·   29 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 9/23/13  Biocept Inc                       S-1¶                  71:6.2M                                   Donnelley … Solutions/FA

Initial Public Offering (IPO):  Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1         Registration Statement (General Form)               HTML   1.65M 
71: COVER     ¶ Comment-Response or Cover Letter to the SEC         HTML     85K 
 2: EX-3.1      Articles of Incorporation/Organization or By-Laws   HTML     77K 
 3: EX-3.1.1    Articles of Incorporation/Organization or By-Laws   HTML     28K 
 4: EX-3.1.2    Articles of Incorporation/Organization or By-Laws   HTML     27K 
 5: EX-3.1.3    Articles of Incorporation/Organization or By-Laws   HTML     35K 
 6: EX-3.2      Articles of Incorporation/Organization or By-Laws   HTML    150K 
 7: EX-3.2.1    Articles of Incorporation/Organization or By-Laws   HTML     86K 
 8: EX-10.1     Material Contract                                   HTML    130K 
 9: EX-10.1.1   Material Contract                                   HTML     69K 
10: EX-10.1.2   Material Contract                                   HTML     52K 
23: EX-10.10    Material Contract                                   HTML     27K 
24: EX-10.11    Material Contract                                   HTML    192K 
25: EX-10.11.1  Material Contract                                   HTML    100K 
26: EX-10.11.2  Material Contract                                   HTML     32K 
27: EX-10.11.3  Material Contract                                   HTML     57K 
28: EX-10.11.4  Material Contract                                   HTML     30K 
29: EX-10.11.5  Material Contract                                   HTML     37K 
30: EX-10.11.6  Material Contract                                   HTML     60K 
31: EX-10.12    Material Contract                                   HTML     89K 
32: EX-10.13    Material Contract                                   HTML    130K 
33: EX-10.14    Material Contract                                   HTML    111K 
34: EX-10.14.1  Material Contract                                   HTML     56K 
35: EX-10.15    Material Contract                                   HTML     83K 
36: EX-10.16    Material Contract                                   HTML     52K 
37: EX-10.16.1  Material Contract                                   HTML     37K 
38: EX-10.16.1.1  Material Contract                                 HTML     20K 
39: EX-10.16.2  Material Contract                                   HTML     51K 
40: EX-10.16.3  Material Contract                                   HTML    278K 
41: EX-10.17    Material Contract                                   HTML     32K 
42: EX-10.17.1  Material Contract                                   HTML     51K 
43: EX-10.17.2  Material Contract                                   HTML     33K 
44: EX-10.17.3  Material Contract                                   HTML     54K 
45: EX-10.18    Material Contract                                   HTML     70K 
46: EX-10.18.1  Material Contract                                   HTML     41K 
47: EX-10.18.2  Material Contract                                   HTML     44K 
48: EX-10.18.3  Material Contract                                   HTML     35K 
49: EX-10.18.4  Material Contract                                   HTML     27K 
50: EX-10.18.5  Material Contract                                   HTML     26K 
51: EX-10.18.6  Material Contract                                   HTML     38K 
52: EX-10.18.6.1  Material Contract                                 HTML     37K 
53: EX-10.18.6.2  Material Contract                                 HTML     72K 
54: EX-10.18.7  Material Contract                                   HTML     51K 
55: EX-10.19    Material Contract                                   HTML     63K 
56: EX-10.19.1  Material Contract                                   HTML     35K 
57: EX-10.19.2  Material Contract                                   HTML     35K 
58: EX-10.19.2.1  Material Contract                                 HTML     36K 
59: EX-10.19.3  Material Contract                                   HTML     51K 
60: EX-10.19.4  Material Contract                                   HTML     20K 
11: EX-10.2     Material Contract                                   HTML    143K 
12: EX-10.2.1   Material Contract                                   HTML     26K 
13: EX-10.2.2   Material Contract                                   HTML     65K 
14: EX-10.2.3   Material Contract                                   HTML     43K 
15: EX-10.2.4   Material Contract                                   HTML     45K 
16: EX-10.2.5   Material Contract                                   HTML     41K 
61: EX-10.20    Material Contract                                   HTML     57K 
62: EX-10.20.1  Material Contract                                   HTML     35K 
63: EX-10.20.2  Material Contract                                   HTML     51K 
64: EX-10.21    Material Contract                                   HTML     38K 
65: EX-10.21.1  Material Contract                                   HTML     53K 
66: EX-10.21.2  Material Contract                                   HTML     29K 
67: EX-10.22    Material Contract                                   HTML     73K 
68: EX-10.23    Material Contract                                   HTML     60K 
17: EX-10.3     Material Contract                                   HTML     88K 
18: EX-10.4     Material Contract                                   HTML     68K 
19: EX-10.5     Material Contract                                   HTML     38K 
20: EX-10.6     Material Contract                                   HTML    105K 
21: EX-10.7     Material Contract                                   HTML    116K 
22: EX-10.8     Material Contract                                   HTML    124K 
69: EX-21.1     Subsidiaries                                        HTML     16K 
70: EX-23.1     Consent of Experts or Counsel                       HTML     17K 


‘EX-10.17’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-10.17  

Exhibit 10.17

AMENDED AND RESTATED LOAN AGREEMENT

BETWEEN

GOODMAN CO. LTD.

AND

BIOCEPT, INC.

WHEREAS, Biocept, Inc., a California corporation (“Borrower”) and Goodman Co. Ltd. (“Lender”) are parties to that certain Amended and Restated Loan Agreement dated January 29, 2009 (the “Prior Loan Agreement”), which amended and restated that certain Amended and Restated Loan Agreement dated June 26, 2007 (the “First Amended Loan Agreement”), which amended and restated that certain Loan Agreement dated April 20, 2005;

WHEREAS, the Lender has agreed to amend the terms of the Prior Loan Agreement effective on the Effective Date (as defined below) in order to extend the Maturity Date (as defined below), amend the timing of payments made by Borrower to Lender, and to provide for such other amendments as provided for herein; and

WHEREAS, in order to document these amendments, Borrower and Lender desire to amend and restate in its entirety the Prior Loan Agreement and to accept the rights and obligations created pursuant hereto in lieu of the rights and obligations granted them under the Prior Loan Agreement.

NOW THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, the parties to the Prior Loan Agreement hereby agree that the Prior Loan Agreement shall be superseded and replaced in its entirety by this Amended and Restated Loan Agreement, and the parties hereto further agree as follows:

1. Promise to Pay. Borrower hereby unconditionally promises to pay to the order of Lender in lawful money of the United States of America and in immediately available funds, the principal sum of Three Million Dollars ($3,000,000.00) (the “Loan”), together with accrued and unpaid interest thereon, due and payable as set forth below. Once repaid, amounts under the Loan may not be reborrowed.

2. Funding. On April 20, 2005 (the “Closing Date”), Lender credited by wire transfer the full principal amount of the Loan at such time to Borrower’s account with such bank as Borrower specified in writing to Lender.

3. Interest.

(a) From the date of execution of the First Amended Loan Agreement through January 31, 2009, interest accrued in the amount of and was paid in accordance with the First Amended Loan Agreement.

(b) From February 1, 2009 through April 30, 2010, interest began accruing on all amounts outstanding under the Loan at the rate of the variable rate of interest, per annum, published as the “prime lending rate” in the Wall Street Journal (the “Prior Interest Obligation”).

 

1


The accrued Prior Interest Obligation was due and payable quarterly in arrears on the last business day of each three-month quarter beginning February 1, 2009 through April 30, 2010 and was calculated on the basis of a 365 day year for the actual number of days elapsed.

(c) On the Effective Date, Borrower shall pay Lender all unpaid interest which has accrued under the Loan pursuant to Section 3(a) and 3(b) above.

(d) Following April 30, 2010, interest began accruing on all amounts outstanding under the Loan at the fixed rate of 3.25% per annum (the “Revised Interest Obligation”). The accrued Revised Interest Obligation shall be due and payable quarterly in arrears on the last business day of each three-month quarter beginning May 1, 2010 and shall be calculated on the basis of a 365 day year for the actual number of days elapsed.

4. Effective Date Balloon Payment. On the Effective Date, Borrower shall pay Lender $750,000, which such amount shall be credited towards the principal balance outstanding under the Loan, such that immediately following the Effective Date, the principal sum of $2,250,000 shall be outstanding under the Loan.

5. Quarterly Principal Payments. Beginning May 1, 2010, Borrower shall pay Lender the applicable Quarterly Principal Payment, which such amount shall be due and payable quarterly in advance on the first business day of each three-month quarter beginning on May 1, 2010, which such amount shall be credited towards the principal balance outstanding under the Loan; provided, however, that the parties hereby agree that the Quarterly Principal Payment otherwise due and payable on May 3, 2010 shall be paid to Lender on the Effective Date. The “Quarterly Principal Payment” shall be an amount equal to:

(a) for payments due and payable during the period between May 1, 2010 through December 31, 2011, the Quarterly Principal Payment shall be an amount equal to $45,000;

(b) for payments due and payable during the period between January 1, 2012 through December 31, 2013, the Quarterly Principal Payment shall be an amount equal to $90,000; and

(c) for payments due and payable during the period between January 1, 2014 through the Maturity Date, the Quarterly Principal Payment shall be an amount equal to $150,000.

6. Maturity. On the earliest to occur of (a) the tenth anniversary of the Closing Date, (b) the date immediately prior to Borrower’s closing of an Acquisition or Asset Transfer (each as defined in Borrower’s Amended and Restated Articles of Incorporation), or (c) the first business day following the closing of an equity financing transaction involving the sale by the Borrower of its equity securities, or securities that are otherwise convertible into equity securities of the Borrower, in which the Borrower receives an aggregate of at least $25,000,000 in cumulative gross proceeds, any principal and interest amounts that remain outstanding under the Loan shall be fully due and payable (the “Maturity Date”).

7. Prepayment. Borrower at any time may prepay any principal amounts in whole or in part, together with the interest on the amount being prepaid up to the date of such payment, without penalty or premium.

8. Place of Payment. Unless another place of payment shall be specified in writing by Lender, all amounts payable hereunder shall be paid by wire transfer to Lender’s account with RESONA BANK, LIMITED IMAIKE BRANCH as provided below:

 

2


RESONA BANK, LIMITED IMAIKE BRANCH

5-1-5 IMAIKE, CHIKUSA-KU, NAGOYA, JAPAN

Telegraphic Address: N/A

ABA Routing Number (SWIFT Address): DIWAJPT

Beneficiary Name: GOODMAN CO., LTD.

                                 108 Fujigaoka, Meito-ku, Nagoya 465-0032 Japan

Account Number: 103571

Telephone: +81(52)774-4350

9. Application of Payments. Except as otherwise provided for in Section 4 and Section 5, payments under this Amended and Restated Loan Agreement shall be applied first to accrued interest, and thereafter to the outstanding principal balance hereof.

10. Preferred Stock Warrant. In exchange for entering into the Prior Loan Agreement, Borrower issued Lender a Warrant to Purchase Preferred Stock, exercisable for 1,000,000 shares of the Borrower’s Series AA Preferred Stock.

11. Security Agreement. In exchange for entering into this Amended and Restated Loan Agreement, Borrower and Lender shall enter into a Subordinated Security Agreement, substantially in the form attached hereto as Exhibit A (the “Security Agreement”), pursuant to which any principal and interest amounts that remain outstanding under the Loan shall be secured by a security interest in the assets of the Borrower as provided for in the Security Agreement.

12. Binding Arbitration. Any dispute regarding this Amended and Restated Loan Agreement shall be resolved by binding arbitration. Any such arbitration shall be conducted under the auspices of the International Arbitration Association and such proceedings shall be conducted under the Rules of Conciliation and Arbitration of the International Chamber of Commerce.

13. Choice of Law. This Amended and Restated Loan Agreement shall be construed in accordance with the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

 

3


IN WITNESS WHEREOF, the parties hereto have caused this Amended and Restated Loan Agreement to be executed on May 18, 2010 (the “Effective Date”).

 

BORROWER

     

LENDER

BIOCEPT, INC.

     

GOODMAN CO. LTD.

By: /s/ S. M. Coutts

     

By: /s/ Takehito Yogo

Name: Stephen M. Coutts

     

Name: Takehito Yogo

Title: President & CEO

     

Title: President & CEO

[SIGNATURE PAGE TO AMENDED AND RESTATED LOAN AGREEMENT]

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-1’ Filing    Date    Other Filings
1/1/14
12/31/1310-K
Filed on:9/23/13DRS
1/1/12
12/31/11
5/18/10
5/3/10
5/1/10
4/30/10
2/1/09
1/31/09
1/29/09
6/26/07
4/20/05
 List all Filings 


29 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/14/23  Biocept Inc.                      10-Q        6/30/23   60:8.5M                                   Donnelley … Solutions/FA
 5/23/23  Biocept Inc.                      S-1/A                  6:538K                                   Donnelley … Solutions/FA
 5/19/23  Biocept Inc.                      S-1/A                  6:451K                                   Donnelley … Solutions/FA
 5/16/23  Biocept Inc.                      S-1/A                  6:451K                                   Donnelley … Solutions/FA
 5/15/23  Biocept Inc.                      S-1/A                  8:709K                                   Donnelley … Solutions/FA
 5/10/23  Biocept Inc.                      10-Q        3/31/23   58:6.8M                                   Donnelley … Solutions/FA
 4/20/23  Biocept Inc.                      S-1                    4:345K                                   Donnelley … Solutions/FA
 4/17/23  Biocept Inc.                      10-K       12/31/22   72:11M                                    Donnelley … Solutions/FA
 4/17/23  Biocept Inc.                      10-Q/A      9/30/22   66:12M                                    Donnelley … Solutions/FA
11/21/22  Biocept Inc.                      10-Q        9/30/22   60:7.7M                                   ActiveDisclosure/FA
11/18/22  Biocept Inc.                      8-K:5      11/17/22   10:135K                                   Donnelley … Solutions/FA
11/10/22  Biocept Inc.                      10-Q        6/30/22   62:7.7M                                   ActiveDisclosure/FA
 5/23/22  Biocept Inc.                      10-Q        3/31/22   69:8.2M                                   ActiveDisclosure/FA
 4/08/22  Biocept Inc.                      S-8         4/08/22    4:77K                                    Donnelley … Solutions/FA
 4/05/22  Biocept Inc.                      10-K       12/31/21   88:13M                                    ActiveDisclosure/FA
 2/15/22  Biocept Inc.                      10-Q/A      9/30/21   75:10M                                    ActiveDisclosure/FA
11/16/21  Biocept Inc.                      S-8        11/16/21    3:185K                                   ActiveDisclosure/FA
11/15/21  Biocept Inc.                      10-Q        9/30/21   70:9.4M                                   ActiveDisclosure/FA
 8/16/21  Biocept Inc.                      10-Q        6/30/21   71:9.7M                                   ActiveDisclosure/FA
 5/12/21  Biocept Inc.                      10-Q        3/31/21   70:6.8M                                   ActiveDisclosure/FA
 3/31/21  Biocept Inc.                      10-K       12/31/20   81:11M                                    ActiveDisclosure/FA
12/23/20  Biocept Inc.                      S-8        12/23/20    4:587K                                   ActiveDisclosure/FA
11/16/20  Biocept Inc.                      10-Q        9/30/20   70:8.7M                                   ActiveDisclosure/FA
 8/13/20  Biocept Inc.                      10-Q        6/30/20   72:9.3M                                   ActiveDisclosure/FA
12/27/13  SEC                               UPLOAD10/13/17    1:160K Biocept Inc.
11/22/13  SEC                               UPLOAD10/13/17    1:164K Biocept Inc.
11/15/13  SEC                               UPLOAD10/13/17    1:144K Biocept Inc.
10/30/13  SEC                               UPLOAD10/13/17    1:148K Biocept Inc.
10/11/13  SEC                               UPLOAD10/13/17    1:185K Biocept Inc.
Top
Filing Submission 0001193125-13-374871   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 10, 2:35:35.2am ET